Provided By GlobeNewswire
Last update: May 9, 2025
Initial proof-of-concept data from the ongoing BBI-355 Phase 1/2 POTENTIATE trial in patients with oncogene-amplified cancers anticipated in the second half of 2025
Read more at globenewswire.comNASDAQ:BOLD (9/22/2025, 9:53:00 AM)
1.147
+0.01 (+0.61%)
Find more stocks in the Stock Screener